Global Hepatocellular Carcinoma Drugs Market 2017-2021

  • ID: 4395271
  • Report
  • Region: Global
  • 86 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bayer
  • Celgene
  • F. Hoffmann-la Roche
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • MORE
About Hepatocellular Carcinoma Drugs

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

The analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer
  • Eli Lilly
  • Johnson and Johnson
  • Pfizer
Other prominent vendors
  • Bristol-Myers Squibb
  • Celgene
  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Salix Pharmaceuticals
  • Transgene
Market drivers
  • Growing cases of hepatitis B and C infections
  • For a full, detailed list, view the full report
Market challenges
  • Stringent government regulations and trial failure in the late stage of drug development
  • For a full, detailed list, view the full report
Market trends
  • Increase in R&D activities for liver cirrhosis medication
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer
  • Celgene
  • F. Hoffmann-la Roche
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape
  • Market size and forecast
  • Five forces analysis
PART 06: Pipeline landscape

PART 07: Market segmentation by therapy
  • Chemotherapy
  • Brachytherapy
  • Ablation therapy
PART 08: Geographical segmentation
  • HCC drugs market in Americas
  • HCC drugs market in EMEA
  • HCC drugs market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Increase in R&D activities for liver cirrhosis medication
  • Rise in awareness
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • Bayer
  • Eli Lilly
  • Johnson and Johnson
  • Pfizer
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Functions of liver
Exhibit 02: Causes of HCC
Exhibit 03: Global HCC drugs market
Exhibit 04: Global HCC drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global HCC drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline based on vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global HCC drugs market segmentation based on therapies
Exhibit 10: Global HCC drugs market share as per therapies 2016 and 2021
Exhibit 11: Major types of chemotherapy
Exhibit 12: Global HCC chemotherapy drugs market 2016-2021 ($ millions)
Exhibit 13: NEXAVAR: Drug overview
Exhibit 14: STIVARGA: Drug overview
Exhibit 15: Global HCC brachytherapy drugs market 2016-2021 ($ millions)
Exhibit 16: Global HCC ablation therapy market 2016-2021 ($ millions)
Exhibit 17: Global HCC drugs market share by geography 2016 and 2021
Exhibit 18: Global HCC drugs market revenues by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: HCC drugs market in Americas 2016-2021 ($ millions)
Exhibit 21: Liver cancer scenario in the US 2016
Exhibit 22: Market scenario in EMEA
Exhibit 23: HCC drugs market in EMEA 2016-2021 ($ millions)
Exhibit 24: Top five countries with highest incidence of liver cancer
Exhibit 25: Market scenario in APAC
Exhibit 26: HCC drugs market in APAC 2016-2021 ($ millions)
Exhibit 27: Proportions of HBV and HCV-related HCC in APAC
Exhibit 28: Hepatitis C scenario 2016
Exhibit 29: Hepatitis B scenario 2016
Exhibit 30: Lifestyle disease effect on liver
Exhibit 31: Global liver transplants scenario 2014
Exhibit 32: Percentage distribution of transplants by organ in the US 1988-2016
Exhibit 33: Effects of chemotherapy drugs on human body
Exhibit 34: Competitive structure analysis of global HCC drugs market 2016
Exhibit 35: Strategic success factors of companies in global HCC drugs market
Exhibit 36: Bayer: Key highlights
Exhibit 37: Bayer: Strength assessment
Exhibit 38: Bayer: Strategy assessment
Exhibit 39: Bayer: Opportunity assessment
Exhibit 40: Eli Lilly: Key highlights
Exhibit 41: Eli Lilly: Strength assessment
Exhibit 42: Eli Lilly: Strategy assessment
Exhibit 43: Eli Lilly: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Pfizer: Key highlights
Exhibit 49: Pfizer: Strength assessment
Exhibit 50: Pfizer: Strategy assessment
Exhibit 51: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bayer
  • Celgene
  • F. Hoffmann-la Roche
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • MORE
New Report Released: - Global Hepatocellular Carcinoma Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global hepatocellular carcinoma drugs market: Bayer, Eli Lilly, Johnson and Johnson, and Pfizer.

Other Prominent Vendors in the market are: Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, Novartis, Salix Pharmaceuticals, and Transgene.

Commenting on the report, an analyst from the research team said: “One trend in the market is increase in R&D activities for liver cirrhosis medication. The need for efficacious and better-tolerated medications drives R&D in the global liver cirrhosis medication market. The growing incidence of the disease represents significant opportunities for market growth. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition.”

According to the report, one driver in the market is growing cases of hepatitis B and C infections. HCC development has been related with many etiological conditions such as alcohol, hepatitis virus, and cirrhosis. Chronic infection with HBV and HCV often leads to cirrhosis which further enhances the probability of developing HCC. HBV is a DNA virus that integrates into host genome this is believed to be carcinogenic. On the other hand, HCV is an RNA virus, it does not integrate with the host genome however, it still induces HCC through inflammatory response to the virus or through host protein interaction.

Further, the report states that one challenge in the market is stringent government regulations and trial failure in the late stage of drug development. Drug approval processes are stringent worldwide, demanding evidence from clinical trial studies. Regulatory authorities carefully study and evaluate the safety, efficacy, pharmacological data, pharmacodynamic effects, and interactions of drugs before approving them for use. A drug failing any of these criteria is likely to receive a complete response letter (CRL) or face complete rejection from regulatory agencies. On receiving a CRL, a drug applicant is required to furnish any additional data pertaining to the drug, which includes additional clinical trials, thereby increasing the R&D expenditure on the drug.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bayer
  • Eli Lilly
  • Johnson and Johnson
  • Pfizer
  • Bristol-Myers Squibb
  • Celgene
  • F. Hoffmann-la Roche
  • Gilead
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Salix Pharmaceuticals
  • Transgene
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll